Skip to main content
APLMW logo

Apollomics, Inc. (APLMW) Stock Price & Analysis

Apollomics, Inc. (APLMW) — price $0.01 (-4.76%), as of the Nov 18, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.01 −$0.0005 (-4.76%)

Apollomics, Inc. · APLMW

Apollomics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of oncology therapies. The company addresses unmet medical needs in the oncology space.

Price as of Nov 18, 2026

Key Statistics

Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • NVO · Novo Nordisk A/S · 87 /100
  • VRTX · Vertex Pharmaceuticals Incorporated · 90 /100
  • REGN · Regeneron Pharmaceuticals, Inc. · 95 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.01
Change on the day-4.76%
52-week range$0.0063 – $0.23
Shares traded on the day20.1K

Price & events

Other perspectives

Council score for Apollomics (APLMW): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Sep 3, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Strong
Gross Margin Negative

Read on: May 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On May 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Apollomics (APLMW), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Apollomics, Inc. (APLMW) is the company analyzed here. It employs 14 people and is led by Hung-Wen Chen. In Q2 FY2025 it reported revenue of $9M and net income of -$13M.

2 · Latest results

What do the latest results show for Apollomics (APLMW)?

Short answer · as of

The most recent reported quarter, Q2 FY2025, carried revenue of $9M.

Quarterly income statement — 1 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2025$9M-$13M-$11.37 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Apollomics (APLMW)?

Short answer · as of

The distress and quality screens read Piotroski F 0. Trailing ratios: ROE 103.1% · current ratio 0.15 · earnings yield -18.8% · free-cash-flow yield -34.9%.

4 · What to check next?

What should you watch next at Apollomics (APLMW)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $237,164 · EPS -122.00 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$237,164
EPS estimate
$-122.00

Measured against a quoted price of $0.01 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 15, 2026

Transactions
52
Identified insiders
9
Purchases
5
Sales
0
Other transactions
47

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held APLMW in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported APLMW in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Apollomics Stock: Key Questions Answered

These answers are editorial: 1 of these 1 answer is drawn from the APLMW research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What do analysts say about APLMW stock?

Analyst coverage of Apollomics, Inc. (APLMW) is limited due to its size and stage of development. However, the consensus view is that the company's success hinges on the outcome of its clinical trials and regulatory approvals.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 8 from Financial Modeling Prep (FMP) and 8 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.